StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Tagrisso (osimertinib) — US product sales by Quarter

Tagrisso (osimertinib) — US product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Tagrisso (osimertinib) — US product sales: $845M in Q2 2026, up 11.0% from a year earlier. That is the highest of the 23 quarters on record here.

Latest, Q2 2026
845
Period ended Jun 30, 2026
Change on a year earlier
+11.0%
761 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Tagrisso | 1,941 | | 7 | | 6 | | 845 | | 11 | | 512 | | 5 | | 1 | | 383 | | 9 | | 4 | | 201 | | ( 3 ) | | 2”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTagrisso (osimertinib) — US product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026845+11.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026733+8.1%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025841+9.6%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025784+9.8%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025761+15.7%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025678+8.8%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024767+28.5%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024714+23.7%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024658+13.3%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024623+19.6%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023597+11.6%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023577+10.7%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023581+13.3%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023521+18.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022535+10.1%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022521+18.1%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up tagrisso (osimertinib) — US product sales

Cite this data

StockData. (2026). AstraZeneca Tagrisso (osimertinib) — US product sales ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tagrisso-us

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.